In our clinical setting, TT with MEK-inhibitor cobimetinib in a patient with ectomesenchymoma-harboring HRAS p.R61Q genetic variant leading to RAS–RAF–MEK pathway activation was unsuccessful. Here, MAP2K7 is linked to ectomesenchymoma.